Treatment of one case of malignant melanoma with N-retinoylarabinocytidine

The synthesis of N-retinoylara-C is described. It is a new anticancer agent which was found to cause disease-free survival of more than three years duration in a patient with malignant melanoma of the nose, incompletely excised with metastasis to submandibular lymph nodes. He received a total of 1200 mg within 6 months, 50 mg weekly, IM. He developed minimal hypervitaminosis A syndrome [somnolence, conjunctivitis and splenomegaly] which recovered a few months after termination of therapy